c2.NIKOLSKY BREAST CANCER 21Q22 AMPLICON c2.REACTOME SIGNALING BY BMP c2.REACTOME G ALPHA 12 13 SIGNALLING EVENTS c2.REACTOME NUCLEAR PORE COMPLEX NPC DISASSEMBLY c2.WP PARKINSONS DISEASE PATHWAY c2.ABBUD LIF SIGNALING 1 UP c2.PHONG TNF RESPONSE VIA P38 PARTIAL	3	nd epithelioid	Gliomas	oneuronal tum	
C2.WP OVERVIEW OF NANOPARTICLE EFFECTS C2.WP CHOLESTEROL SYNTHESIS DISORDERS C2.KEGG MEDICUS PATHOGEN HTLV 1 TAX TO E47 MEDIATED TRANSCRIPTION C2.REACTOME RECOGNITION AND ASSOCIATION OF DNA GLYCOSYLASE WITH SITE CONTAINING AN AFFECTED PURINE C2.OHM EMBRYONIC CARCINOMA DN C2.KEGG MEDICUS REFERENCE GLYCOGEN DEGRADATION AMYLASE C2.RUAN RESPONSE TO TNF DN C2.REACTOME SHC MEDIATED CASCADE FGFR3 C2.REACTOME SHC MEDIATED CASCADE FGFR3 C2.REACTOME NUCLEAR IMPORT OF REV PROTEIN C2.WP REGULATION OF SISTER CHROMATID SEPARATION AT THE METAPHASEANAPHASE TRANSITION C2.LANDIS BREAST CANCER PROGRESSION UP C2.BONOME OVARIAN CANCER SURVIVAL OPTIMAL DEBULKING C2.PEART HDAC PROLIFERATION CLUSTER DN C2.REACTOME RNA POLYMERASE III CHAIN ELONGATION C2.REACTOME CO28 DEPENDENT PI3K AKT SIGNALING C2.LEE RECENT THYMIC EMIGRANT C2.REACTOME CO28 DEPENDENT PI3K AKT SIGNALING C2.LEE RECENT THYMIC EMIGRANT C2.REACTOME INTEGRIN CELL SURFACE INTERACTIONS C2.KEGG MEDICUS REFERENCE CD80 CD86 CD28 PI3K SIGNALING PATHWAY					
c2.WORSCHECH TUMOR REJECTION DN c2.NOUSHMEHR GBM GERMLINE MUTATED c2.MOSSHMEHR GBM GERMLINE MUTATED c2.MISSIAGLIA REGULATED BY METHYLATION DN c2.HESS TARGETS OF HOXA9 AND MEIS1 UP c2.HESS TARGETS OF HOXA9 AND MEIS1 UP c2.HIRSCH CELLULAR TRANSFORMATION SIGNATURE UP c2.PYEON HPV POSITIVE TUMORS DN c2.WP IMMUNE RESPONSE TO TUBERCULOSIS c2.CHEBOTIAEV GR TARGETS UP c2.WEI MYCN TARGETS WITH E BOX c2.WP OPIOID RECEPTOR PATHWAYS c2.LIM MAMMARY LUMINAL PROGENITOR DN c2.KEGG MEDICUS REFERENCE AUTOPHAGY VESICLE NUCLEATION ELONGATION MATURATION P13P SYNTHESIS BY P13KC3 C1 c2.WP IL10 ANTIINFLAMMATORY SIGNALING c2.MULLIGHAN MLL SIGNATURE 1 UP c2.BROWLE HOW INFECTION 48HR DN c2.WANG SMARCE1 TARGETS DN c2.NUNODA RESPONSE TO DASATINIB IMATINIB DN c2.LIM MAMMARY STEM CELL UP					
C2.KEGG MEDICUS REFERENCE IFN RIPK1 3 SIGNALING PATHWAY C2.KEGG MEDICUS PATHOGEN SALMONELLA SIFA TO TETHERING OF LATE ENDOSOMES AND LYSOSOMES C2.WIKMAN ASBESTOS LUNG CANCER DN C2.PASQUALUCCI LYMPHOMA BY GC STAGE DN C2.FASOR TAMOXIFEN RESPONSE DN C2.FASOR TAMOXIFEN RESPONSE DN C2.REACTOME NOREPINEPHRINE NEUROTRANSMITTER RELEASE CYCLE C2.ZHAN MULTIPLE MYELOMA MS DN C2.HEBERT MATRISOME TNBC LUNG METASTASIS C2.WP TAR SYNDROME C2.REACTOME TRANSMISSION ACROSS CHEMICAL SYNAPSES C2.BLANCO MELO COVID19 SARS COV 2 POS PATIENT LUNG TISSUE DN C2.BROWN MYELOID CELL DEVELOPMENT UP C2.KEGG MEDICUS REFERENCE IFN TG SIGNALING PATHWAY C2.REACTOME ADENYLATE CYCLASE INHIBITORY PATHWAY C2.FIGUEROA AML METHYLATION CLUSTER 3 DN C2.KEGG MEDICUS VARIANT TEL AML1 FUSION TO TRANSCRIPTIONAL REPRESSION					
c2.YAO TEMPORAL RESPONSE TO PROGESTERONE CLUSTER 8 c2.WP BMP SIGNALING IN EYELID DEVELOPMENT c2.MAGRANGEAS MULTIPLE MYELOMA IGLL VS IGLK UP c2.WP EMBRYONIC STEM CELL PLURIPOTENCY PATHWAYS c2.WP GENETIC CAUSES OF PORTOSINUSOIDAL VASCULAR DISEASE c2.BENPORATH CYCLING GENES c2.CHIBA RESPONSE TO TSA UP c2.KEGG MEDICUS REFERENCE AUTOPHAGY VESICLE NUCLEATION ELONGATION MATURATION LC3 II FORMATION c2.REACTOME FRS MEDIATED FGFRS SIGNALING c2.PID PLK1 PATHWAY c2.KEGG MEDICUS REFERENCE IL1 IL1R P38 SIGNALING PATHWAY c2.FARMER BREAST CANCER APOCRINE YS LUMINAL c2.FARMER BREAST CANCER APOCRINE FATHWAY c2.WALLACE PROSTATE CANCER UP c2.LIN NPAS4 TARGETS UP c2.TAYLOR METHYLATED IN ACUTE LYMPHOBLASTIC LEUKEMIA c2.KEGG MEDICUS REFERENCE CA2 CAM VGCC RYR SIGNALING PATHWAY	90000				
C2.XU HGF SIGNALING NOT VIA AKT1 6HR C2.WP CONVERSION OF ANGIOTENSIONGEN TO ANGIOTENSIN II C2.REACTOME PHENYLALANINE METABOLISM C2.REACTOME PHENYLALANINE METABOLISM C2.REACTOME RIBAVIRIN ADME C2.GRAHAM CML QUIESCENT VS CML DIVIDING UP C2.EPPERT HSC R C2.KAMMINGA EZH2 TARGETS C2.GAZDA DIAMOND BLACKFAN ANEMIA ERYTHROID UP C2.VANTVEER BREAST CANCER METASTASIS DN C2.MARKEY RB1 ACUTE LOF DN C2.REACTOME INTERFERON GAMMA SIGNALING C2.SMID BREAST CANCER RELAPSE IN BONE UP C2.WP ESTROGEN METABOLISM WP5276 C2.HELLER HDAC TARGETS SILENCED BY METHYLATION DN C2.HOSHIDA LIVER CANCER SURVIVAL DN C2.KEGG MEDICUS REFERENCE KISS1 KISS1R PLCB PKC SIGNALING PATHWAY					
c2.WP CHOLESTEROL BIOSYNTHESIS PATHWAY c2.SHETH LIVER CANCER VS TXNIP LOSS PAM3 c2.REACTOME SHC MEDIATED CASCADE FGFR4 c2.DAVICIONI PAX FOXO1 SIGNATURE IN ARMS UP c2.UNTERMAN IPF VS CTRL MONOCYTE DN c2.WP SMITHMAGENIS AND POTOCKILUPSKI SYNDROME COPY NUMBER VARIATION c2.REACTOME ANCHORING FIBRIL FORMATION c2.REACTOME ANCHORING FIBRIL FORMATION c2.BEGUM TARGETS OF PAX3 FOXO1 FUSION UP c2.ROSS AML WITH MLL FUSIONS c2.BREDEMEYER RAG SIGNALING NOT VIA ATM UP c2.ACEVEDO LIVER CANCER DN c2.ACEVEDO LIVER CANCER DN c2.KANNAN TP53 TARGETS UP c2.KEACTOME NEUROTRANSMITTER RELEASE CYCLE c2.WP RESOLVIN E1 AND RESOLVIN D1 SIGNALING DECREASE INFLAMMATION					
C2.WP RESOLVIN ET AND RESOLVIN DE SIGNALING DECREASE INFLAMMATION c2.REACTOME SYNTHESIS SECRETION AND INACTIVATION OF GLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE GIP c2.WEST ADRENOCORTICAL TUMOR DN c2.SCHWAB TARGETS OF BMYB POLYMORPHIC VARIANTS UP c2.GAUTSCHI SRC SIGNALING c2.KEGG MEDICUS REFERENCE REGULATION OF GF RTK RAS ERK SIGNALING PTP c2.PASTURAL RI21 TARGETS DN c2.JAEGER METASTASIS UP c2.PID EPHRINB REV PATHWAY c2.KEGG MEDICUS REFERENCE MGLURI TRPC3 SIGNALING PATHWAY c2.KEGG MEDICUS REFERENCE MGLURI TRPC3 SIGNALING PATHWAY c2.KEGG PATHWAYS IN CANCER c2.KEGG PATHWAYS IN CANCER c2.FARMER BREAST CANCER CLUSTER 3 c2.REACTOME OTHER INTERLEUKIN SIGNALING c2.BLANCO MELO COVID19 SARS COV 2 INFECTION A594 ACE2 EXPRESSING CELLS DN c2.MIDORISMA AMPLIFIED IN LIVER CANCER			10 00 00 00 00 00 00 00 00 00 00 00 00 0		
c2.LIU CMYB TARGETS UP c2.WP HIPPOMERLIN SIGNALING DYSREGULATION c2.KEGG BUTANDATE METABOLISM c2.WP TYPE III INTERFERON SIGNALING c2.WP TYPE III INTERFERON SIGNALING c2.WP TYPE III INTERFERON SIGNALING c2.WP TCELL RECEPTOR SIGNALING c2.WP TCELL RECEPTOR SIGNALING c2.WP OXIDATIVE DAMAGE RESPONSE c2.BOQUEST STEM CELL UP c2.FIGUEROA AML METHYLATION CLUSTER 7 UP c2.MCCABE HOXC6 TARGETS CANCER UP c2.MCCABE HOXC6 TARGETS CANCER UP c2.KEGG MEDICUS REFERENCE TSC1 2 MTORC1 SIGNALING PATHWAY c2.KEGG MEDICUS REFERENCE TSC1 2 MTORC1 SIGNALING PATHWAY c2.REACTOME GLYCOGEN BREAKDOWN GLYCOGENOLYSIS c2.HORIUCHI WTAP TARGETS UP c2.REACTOME SPHINGOLIPID DE NOVO BIOSYNTHESIS c2.AMIT EGF RESPONSE 120 HELA					
C2.TONKS TARGETS OF RUNX1 RUNX1T1 FUSION GRANULOCYTE UP C2.REACTOME MITOCHONDRIAL BIOGENESIS C2.REACTOME CREATINE METABOLISM C2.REACTOME EXPORT OF VIRAL RIBONUCLEOPROTEINS FROM NUCLEUS C2.KEGG NATURAL KILLER CELL MEDIATED CYTOTOXICITY C2.LI ESTROGENE META E2 RESPONSE DN C2.HASLINGER B CLL WITH MUTATED VH GENES C2.KEGG MEDICUS REFERENCE P27 CELL CYCLE G1 S C2.RODWELL AGING KIDNEY DN C2.BROWNE HCKWI INFECTION 16HR UP C2.AMIT SERUM RESPONSE 60 MCF10A C2.KEGG MEDICUS PATHOGEN HIV TAT NEF TO CROSSTALK BETWEEN EXTRINSIC AND INTRINSIC APOPTOTIC PATHWAYS C2.JIANG MELANOMA TRM4 C2.WALLACE PROSTATE CANCER RACE DN C2.PID 773PATHWAY C2.MCCLUNG DELTA FOSB TARGETS DN C2.HAN SATB1 TARGETS DN C2.LIU VAV3 PROSTATE CARCINGGENESIS DN C2.LIU VAV3 PROSTATE CARCINGGENESIS DN C2.REACTOME SARS COV 2 MODULATES AUTOPHAGY					
C2.WP SMC1SMC3 ROLE IN DNA DAMAGE CORNELIA DE LANGE SYNDROME C2.KEGG MEDICUS VARIANT MLL AF4 FUSION TO TRANSCRIPTIONAL ACTIVATION C2.REACTOME SNRNP ASSEMBLY C2.GARGALOVIC RESPONSE TO OXIDIZED PHOSPHOLIPIDS BLUE UP C2.WP CARDIOMYOCYTE SIGNALING CONVERGING ON TITIN C2.LIU VMYB TARGETS UP C2.KEGG MEDICUS REFERENCE BMP SIGNALING PATHWAY C2.HENDRICKS SMARCA4 TARGETS DN C2.KEGG MEDICUS REFERENCE GLYCOGEN BIOSYNTHESIS C2.WP NEOVASCULARIZATION PROCESSES C2.GRAHAM CML QUIESCENT VS NORMAL DIVIDING UP C2.REACTOME PHOSPHOLIPID METABOLISM C2.KIM MYCL1 AMPLIFICATION TARGETS DN C2.KEGG MEDICUS REFERENCE CCR CXCR GNB G P13K RAC SIGNALING PATHWAY C2.KEGG MEDICUS REFERENCE CCR CXCR GNB G P13K RAC SIGNALING PATHWAY C2.KEGG MEDICUS REFERENCE CCR CXCR GNB G P13K RAC SIGNALING PATHWAY C2.REACTOME TRANSCRIPTIONAL REGULATION BY THE AP 2 TFAP2 FAMILY OF TRANSCRIPTION FACTORS C2.RICKMAN TUMOR DIFFERENTIATED MODERATELY VS POORLY UP					
c2.RHEIN ALL GLUCOCORTICOID THERAPY UP c2.LIU PROSTATE CANCER DN c2.MARTENS BOUND BY PML RARA FUSION c2.MYLLYKANGAS AMPLIFICATION HOT SPOT 21 c2.KEGG MAPK SIGNALING TO IFNA1 DN c2.READAEVA RESPONSE TO IFNA1 DN c2.WP HIPPO SIGNALING REGULATION c2.NEMETH INFLAMMATORY RESPONSE LPS DN c2.REACTOME INTERLEUKIN 37 SIGNALING c2.VECCHI GASTRIC CANCER ADVANCED VS EARLY UP c2.RAY TUMORIGENESIS BY ERSZA DN c2.DESERT PERIVENOUS HEPATOCELLUAR CARCINOMA SUBCLASS UP c2.BIOCARTA IL7 PATHWAY c2.DORMOY ELAVL1 TARGETS c2.WP FATTY ACID BIOSYNTHESIS c2.PID GLYPICAN 1PATHWAY c2.WP ALSTROM SYNDROME					
c2.WP 15Q11Q13 COPY NUMBER VARIATION c2.HUANG GATAZ TARGETS UP c2.LIAO METASTASIS c2.KEGG MEDICUS REFERENCE INACTIVATION OF CONDENSIN II c2.REACTOME RNA POLYMERASE II TRANSCRIBES SNRNA GENES c2.DORSEY GABZ TARGETS c2.KEGG MEDICUS VARIANT AMPLIFIED CCND1 TO CELL CYCLE G1 S c2.WP TRANSCRIPTIONAL ACTIVATION BY NRF2 IN RESPONSE TO PHYTOCHEMICALS c2.MCBRYAN PUBERTAL TGFB1 TARGETS DN c2.CLIMENT BREAST CANCER COPY NUMBER UP c2.PID ALPHA SYNUCLEIN PATHWAY c2.DING LUNG CANCER BY MUTATION RATE c2.KEGG MEDICUS REFERENCE FAS JNK SIGNALING PATHWAY c2.REACTOME INTERLEUKIN 15 SIGNALING c2.WP NRXN1 DELETION SYNDROME c2.REACTOME SEROTONIN NEUROTRANSMITTER RELEASE CYCLE c2.ABE VEGFA TARGETS 2 HR c2.REACTOME SYNTHESIS SECRETION AND DEACYLATION OF GHRELIN					
c2.DACOSTA ERCC3 ALLELE XPCS VS TTD DN c2.REACTOME TOLL LIKE RECC3 ALLELE XPCS VS TTD DN c2.REACTOME TOLL LIKE RECC3 ALLELE XPCS VS TTD DN c2.KEGG INOSITOL PHOSPHATE METABOLISM c2.PID IL5 PATHWAY c2.WP SRF AND MIRS IN SMOOTH MUSCLE DIFFERENTIATION AND PROLIFERATION c2.MULLIGHAN NPM1 MUTATED SIGNATURE 1 UP c2.TARTE PLASMA CELL VS PLASMABLAST UP c2.PUJANA BRCA CENTON TERM TORNOR c2.PUJANA BRCA CENTON TERM TORNOR c2.MEATOM GIST MORPHOLOGICAL SWITCH c2.REACTOME CELL JUNCTION ORGANIZATION c2.WE STON VEGFA TARGETS 6HR c2.FULCHER INFLAMMATORY RESPONSE LECTIN VS LPS DN c2.RIZKI TUMOR INVSIVENESS DD UP c2.KEGG MELANOGENESIS c2.REACTOME GROWTH HORMONE RECEPTOR SIGNALING c2.FONTAINE FOLLICULAR THYROID ADENOMA UP c2.REACTOME FOULLULAR THYROID ADENOMA UP c2.REACTOME ACYL CHAIN REMODELING OF CL					
c2.DARWICHE SKIN TUMOR PROMOTER DN c2.REACTOME POLB DEPENDENT LONG PATCH BASE EXCISION RERAIN c2.DAVICIONI MOLECULAR ARMS VS ERMS DN c2.REACTOME REPRESSION OF WNT TARGET GENES c2.CHASSOT SKIN WOUND c2.KEGG MEDICUS REFERENCE NOD NFKB SIGNALING PATHWAY c2.FEKIR HEPARG SPHERE VS HEPARG UP c2.BIOCARTA REELIN PATHWAY c2.WP INTERACTIONS BETWEEN LOXL4 AND OXIDATIVE STRESS PATHWAY c2.REACTOME 2 LTR CIRCLE FORMATION c2.IWANAGA CARCINOGENESIS BY KRAS UP c2.WP GLUCOCORTICOID RECEPTOR PATHWAY c2.WP CALCIUM REGULATION IN CARDIAC CELLS c2.INGRAM SHH TARGETS DN c2.KEGG MEDICUS REFERENCE ANGII AT1R NOX2 SIGNALING PATHWAY c2.IVANOVA HEMATOPOIESIS LATE PROGENITOR					
c2.RICKMAN TUMOR DIFFERENTIATED WELL VS MODERATELY UP c2.WP TLR4 SIGNALING AND TOLERANCE c2.KEGG MEDICUS REFERENCE EP NE ADRB CAMP SIGNALING ANTHWAY c2.REACTOME ANCHORING OF THE BASAL BODY TO THE PLASMA MEMBRANE c2.TSUNODA CISPLATIN RESISTANCE DN c2.WP EUKARYOTIC TRANSCRIPTION INITIATION c2.REACTOME TETRAHYDROBIOPTERIN BH4 SYNTHESIS RECYCLING SALVAGE AND REGULATION c2.WP ROLES OF CERAMIDES IN DEVELOPMENT OF INSULIN RESISTANCE c2.TSUDA ALVEOLAR SOFT PART SARCOMA c2.ZHAN MULTIPLE MYELOMA HP DN c2.KEGG MEDICUS VARIANT MUTATION INACTIVATED RUNXT TO TRANSCRIPTION c2.WP ACUTE VIRAL MYOCARDITIS c2.SHETH LIVER CANCER VS TXNIP LOSS PAM2 c2.TONKS TARGETS OF RUNX1 RUNX111 FUSION SUSTAINDED IN ERYTHROCYTE UP c2.SENGUPTA NASOPHARYNGEAL CARCINOMA UP c2.SENGUPTA NASOPHARYNGEAL CARCINOMA UP c2.FOSTER TOLERANT MACRIPTION c2.FEACTOME RUNX3 REGULATES YAP1 MEDIATED TRANSCRIPTION					
c2.KEGG MEDICUS VARIANT AMPLIFIED MYCN TO TRANSCRIPTIONAL REPRESSION c2.JAZAERI BREAST CANCER BRCA1 VS BRCA2 DN c2.PLANSFORMED BY RHOA FOREVER DN c2.PLD FOXM1 PATHWAY c2.PURBEY TARGETS OF CTBP1 AMD SATB1 DN c2.REACTOME GAMMA CARBOXYLATION TRANSPORT AND AMINO TERMINAL CLEAVAGE OF PROTEINS c2.WP SUDDEN INFANT DEATH SYNDROME SIDS SUSCEPTIBILITY PATHWAYS c2.REACTOME REGULATION OF GLUCOKINASE BY GLUCOKINASE REGULATORY PROTEINS c2.REACTOME REGULATOR OF PLATELET ADHESION TO EXPOSED COLLAGEN c2.REACTOME ENHANCED BINDING OF GP1BA VARIANT TO VWF MULTIMER COLLAGEN c2.REACTOME ENHANCED BINDING OF GP1BA VARIANT TO VWF MULTIMER COLLAGEN c2.REACTOME ENHANCED BINDING OF SP1BA VARIANT TO WF MULTIMER COLLAGEN c2.ROZANOV MMP14 TARGETS UP c2.DELACROIX RAR TARGETS DN c2.REACTOME FOXO MEDIATED TRANSCRIPTION OF OXIDATIVE STRESS METABOLIC AND NEURONAL GENES c2.KEGG GLUTATHIONE METABOLISM c2.PHONG TNF RESPONSE NOT VIA P38 c2.REACTOME DUAL INCISION IN GG NEER c2.KEGG MEDICUS REFERENCE LIGHT HYEM NERS SIGNALING PATHWAY					
C2. KEGG MEDICUS REFERENCE LIGHT HVEM NFKB SIGNALING PATHWAY c2. REACTOME TRANSCRIPTIONAL REGULATION OF WHITE ADIPOCYTE DIFFERENTIATION c2. REACTOME INTERCONVERSION OF NUCLEOTIDE DI AND TRIPHOSPHATES c2. EHRLICH ICF SYNDROM DN c2. BOYAULT LIVER CANCER SUBCLASS G56 DN c2. TONKS TARGETS OF RUNX1 RUNX111 FUSION ERYTHROCYTE UP c2. BOYLAN MULTIPLE MYELOMA C D UP c2. REACTOME NEGATIVE REGULATION OF NMDA RECEPTOR MEDIATED NEURONAL TRANSMISSION c2. REACTOME ACETYLCHOLINE REGULATES INSULIN SECRETION c2. GAVIN IL2 RESPONSIVE FOXP3 TARGETS DN c2. C2. GAVIN IL2 RESPONSIVE FOXP3 TARGETS DN c2. REACTOME E2F MEDIATED REGULATION OF DNA REPLICATION DN c2. REACTOME E2F MEDIATED REGULATION OF DNA REPLICATION DN c2. REACTOME E2F MEDIATED REGULATION OF DNA REPLICATION DN c2. C2. IZADPANAH STEM CELL ADIPOSE VS BONE DN c2. SANSOM APC MYC TARGETS c2. MONNIER POSTRADIATION TUMOR ESCAPE DN c2. XU GH1 AUTOCRINE TARGETS UP c2. MANALO HYPOXIA UP c2. NIKOLSKY BREAST CANCER 7021 Q22 AMPLICON					
C2.NIKOLSKY BREAST CANCER 7Q21 Q22 AMPLICON C2.TSAI RESPONSE TO IONIZING RADIATION C2.SHETH LIVER CANCER VS TXNIP LOSS PAM6 C2.PID E2F PATHWAY C2.MASSARWEH TAMOXIFEN RESISTANCE UP C2.NIKOLSKY BREAST CANCER 12Q24 AMPLICON C2.MATSUDA NATURAL KILLER DIFFERENTIATION C2.MATSUDA NATURAL KILLER DIFFERENTIATION C2.MEACTOME ION CHANNEL TRANSPORT C2.WP 2Q2112 COPY NUMBER VARIATION SYNDROME C2.TONKS TARGETS OF RUNX1 RUNX1T1 FUSION SUSTAINED IN GRANULOCYTE UP C2.WP GLYCEROPHOSPHOLIPID BIOSYNTHETIC PATHWAY C2.REACTOME RHO GTPASES ACTIVATE NADPH OXIDASES C2.GUO HEX TARGETS DN C2.SENESE HDAC2 TARGETS DN C2.SENESE HDAC2 TARGETS DN C2.VALK AML CLUSTER 4 C2.WP MEVALONATE ARM OF CHOLESTEROL BIOSYNTHESIS PATHWAY C2.CHICAS RBI TARGETS SENESCENT					
C2. GOLDRATH IMMUNE MEMORY C2. KEGG MEDICUS VARIANT MUTATION INACTIVATED TP53 TO TRANSCRIPTION C2. HELLER HDAC TARGETS DN C2. TERAMOTO OPN TARGETS CLUSTER 8 C2. TAKEDA TARGETS OF NUP98 HOXA9 FUSION 6HIP DN C2. PID CASPASE PATHWAY C2. STAMBOLSKY RESPONSE TO VITAMIN D3 UP C2. KOBAYASHI EGFR SIGNALING 6HR DN C2. JAZAG TGFB1 SIGNALING 6HR DN C2. WP GLUCURONIDATION C2. PUJANA BRCA2 PCC NETWORK C2. FUJANA BRCA2 PCC NETWORK C2. REACTOME ION HOMEOSTASIS C2. WP AUTOSOMAL RECESSIVE OSTEOPETROSIS PATHWAYS C2. WP UDPDERIVED SUGARS SYNTHESIS IN FIBROBLASTS C2. MULLIGAN NTF3 SIGNALING VIA INSR AND IGF1R DN C2. KEGG MEDICUS PATHOGEN HIV NEF TO TNF NFKB SIGNALING PATHWAY C2. KEGG MEDICUS PATHOGEN HIV NEF TO TNF NFKB SIGNALING PATHWAY					
C2.KYNG DNA DAMAGE BY GAMMA RADIATION C2.REACTOME TP53 REGULATES TRANSCRIPTION OF DNA REPAIR GENES C2.FULCHER INFLAMMATORY RESPONSE LECTIV VS LPS UP C2.WP ALTERED GLYCOSYLATION OF MUC1 IN TUMOR MICROENVIRONMENT C2.LEE LIVER CANCER MYC TGFA UP C2.SUZUKI AMPLIFIED IN ORAL CANCER C2.REACTOME REGULATION OF HMOX1 EXPRESSION AND ACTIVITY C2.WP REGULATORY CIRCUITS OF STAT3 SIGNALING C2.REACTOME INOSTOL PHOSPHATE METABOLISM C2.REACTOME INTERACTION BETWEEN L1 AND ANKYRINS C2.REACTOME INTERACTION BETWEEN L1 AND ANKYRINS C2.WHOF SIGNALING NOT VIA AKT1 48HR UP C2.MATZUK CENTRAL FOR FEMALE FERTILITY C2.CAIRO HEPATOBLASTOMA CLASSES DN C2.REACTOME TRANSLESION SYNTHESIS BY C2.REACTOME TRANSLESTOM CLASSES DN C2.REACTOME TRANSLESTOM CLASSES DN C2.REACTOME TRANSLESTOM CLASSES DN C2.REACTOME TRAF6 MEDIATORICACTIVATION C2.SMIRNOV RESPONSE TO IR 6HR UP C2.KOKKINAKIS METHHONINE DEPRIVATION 48HR DN C2.REACTOME PEPTIDE HORMONE METABOLISM C2.WP FAMILIAL HYPERLIPIDEMIA TYPE 3					
c2.WANG BARRETTS ESOPHAGUS UP c2.SOTIRIOU BREAST CANCER GRABE 1 VS 2. c2.REACTOME GABB A B RECEPTOR ACTIVATION c2.KEGG MEDICUS REFERENCE TNF NFKB SIGNALING PATHWAY c2.KANG AR TARGETS UP c2.REAGINS TAMOXIFEN RESISTANCE UP c2.REACTOME SOLVALL LIVER CANCER SUBCLASS G23 UP c2.REACTOME SYNTHESIS OF IP3 AND IP4 IN THE CYTOSOL c2.WP AMPLIFICATION AND EXPANSION OF ONCOGENIC PATHWAYS AS METASTATIC TRAITS c2.KUMAR TARGETS OF MLL AF9 FUSION c2.JAZAG TGFB1 SIGNALING VIA SMAD4 UP c2.GEISS RESPONSE TO DSRNA DN c2.MARTORIATI MDM4 TARGETS FETAL LIVER UP c2.FONTAINE FOLLICULAR THYROID ADENOMA DN c2.FONTAINE FOLLICULAR THYROID ADENOMA DN c2.REACTOME NETRIN MEDIATED REPULSION SIGNALS			70000000000000000000000000000000000000		
c2.KRIGE RESPONSE TO TOSEDOSTAT 6HR DN c2.FISCHER DIRECT P53 TARGETS META ANALYSIS c2.DARWICHE SQUAMOUS CELL CARCINOMA DN c2.PURBEY TARGETS OF CTBP1 NOT SATB1 UP c2.WANG METASTASIS OF BREAST CANCER ESR1 UP c2.HEBERT MATRISOME TNBC LIVER METASTASIS c2.WP 11P112 COPY NUMBER VARIATION SYNDROME c2.KEGG MEDICUS REFERENCE FSHR GNAS PKA SIGNALING PATHWAY c2.SENESE HDAC1 AND HDAC2 TARGETS UP c2.GAZDA DIAMOND BLACKFAN ANEMIA ERYTHROID DN c2.WAKABAYASHI ADIPOGENESIS PPARG BOUND 36HR c2.SASAI TARGETS OF CXCR6 AND PTCH1 UP c2.WILSON PROTEASES AT TUMOR BONE INTERFACE DN c2.KEGG MEDICUS REFERENCE DERMATAN SULFATE DEGRADATION c2.REACTOME NEGATIVE REGULATION OF THE P13K AKT NETWORK c2.REACTOME REGULATION OF IFNA IFNB SIGNALING c2.TING SILENCED BY DICER c2.SIGN CELL CYCLE TARGETS OF TP53 AND TP73 UP					
c2.ZHANG ANTIVIRAL RESPONSE TO RIBAVIRIN UP c2.WATANABE COLON CANCER BLUCON CANCER SIS SUP c2.REACTOME GLUCONEOGENESIS c2.PID TAP63 PATHWAY c2.WP METHIONINE DE NOVO AND SALVAGE PATHWAY c2.KRASNOSELSKAYA ILF3 TARGETS DN c2.KEGG NITROGEN METABOLISM c2.YORDY RECIPROCAL REGULATION BY ETS1 AND SP100 DN c2.KASLER HDAC7 TARGETS 1 UP c2.KASLER HDAC7 TARGETS 1 UP c2.HERNANDEZ MITOTIC ARREST BY DOCETAXEL 1 UP c2.MARKEY RB1 CHRONIC LOF UP c2.KEGG NOD LIKE RECEPTOR SIGNALING PATHWAY c2.WP LEUKOCYTEINTRINSIC HIPPO PATHWAY FUNCTIONS c2.HERNANDEZ MITOTIC ARREST BY DOCETAXEL 1 DN c2.KEGG MEDICUS REFERENCE TYPE I IFN SIGNALING PATHWAY c2.WD LEUKOCYTEINTRINSIC HIPPO PATHWAY FUNCTIONS c2.KEGG MEDICUS REFERENCE TYPE I IFN SIGNALING PATHWAY c2.KEGG MEDICUS REFERENCE TYPE I IFN SIGNALING PATHWAY c2.KEGG MEDICUS VARIANT BCL2 OVEREXPRESSION TO INTRINSIC APOPTOTIC PATHWAY					
C2.REACTOME TP53 REGULATES TRANSCRIPTION OF GENES INVOLVED IN CYTOCHROME C RELEASE C2.ZHAN MULTIPLE MYELOMA CD1 AND CD2 UP C2.FONTAINE PAPILLARY THYROID CARCINOMA UP C2.ZHAN MULTIPLE MYELOMA MS UP C2.HAHTOLA SEZARY SYNDROM UP C2.WESTON VEGFA TARGETS C2.GREENBAUM E2A TARGETS UP C2.KEGG MEDICUS VARIANT MUTATION ACTIVATED LRRK2 TO INTRINSIC APOPTOTIC PATHWAY C2.REACTOME NUCLEOTIDE BIOSYNTHESIS C2.LENAOUR DENDRITIC CELL MATURATION UP C2.KEGG MEDICUS VARIANT MUTATION CAUSED ABERRANT SPTBN2 TO MGLUR1 TRPC3 SIGNALING PATHWAY C2.REACTOME CHOLESTEROL BIOSYNTHESIS C2.ELVIDGE HYPOXIA BY DMOG DN C2.REACTOME CHOLESTEROL BIOSYNTHESIS C2.REACTOME CHOLESTEROL BIOSYNTHESIS C2.REACTOME CHOLESTEROL BIOSYNTHESIS C2.REACTOME CHOLESTEROL BIOSYNTHESIS C2.RECKMAN METASTASIS DN C2.RICKMAN METASTASIS DN					
C2.REACTOME PYROPTOSIS C2.REACTOME TRANSPORT OF SMALL MOLECULES C2.LEE BMP2 TARGETS DN C2.WP 2Q112 COPY NUMBER VARIATION SYNDROME C2.RAMJAUN APOPTOSIS BY TGFB1 VIA SMAD4 DN C2.KYNG DNA DAMAGE UP C2.WU CELL MIGRATION C2.JAERVINEN AMPLIFIED IN LARNSMENT MEMBRANES C2.HINATA NFKB TARGETS KERATINOCYTE UP C2.CREGIHTON ENDOCRINE THERAPY RESINCE 3 C2.REACTOME SENSORY PROCESSING OF SOUND BY OUTER HAIR CELLS OF THE COCHLEA C2.KRIGE RESPONSE TO TOSEDOSTAT 24HR DN C2.KEGG MEDICUS REFERENCE VGC CA2 APOPTOTIC PATHWAY C2.BIOCARTA RANKL PATHWAY C2.BIOCARTA RANKL PATHWAY C2.CREACTOME SENSORY DROCESSING OF SOUND LIVER CANCER ARANKL PATHWAY C2.BIOCARTA RANKL PATHWAY C2.COHASHI AURKB TARGETS C2.ZWANG CLASS 1 TRANSIENTLY INDUCED BY EGF					
c2.BENPORATH ES CORE NINE CORRELATED c2.LINDGREN BLADDER CANCER CLUSTER 1 DN c2.REACTOME SYNTHESIS OF PIPS AT THE LATE ENDOSOME MEMBRANE c2.NIKOLSKY BREAST CANCER 17Q11 Q21 AMPLICON c2.WP UREA CYCLE AND METABOLISM OF AMINO GROUPS c2.LIU SMARCA4 TARGETS c2.WP FAMILIAL PARTIAL LIPODYSTROPHY c2.WP ALTERNATIVE PATHWAY OF FETAL ANDROGEN SYNTHESIS c2.KEGG MEDICUS REFERENCE TYPE I INTERFERON TO JAK STAT SIGNALING PATHWAY c2.WP PLEURAL MESOTHELIOMA c2.KEGG ADIPOCYTOKINE SIGNALING PATHWAY c2.WP PLEURAL MESOTHELIOMA c2.KEGG ADIPOCYTOKINE SIGNALING PATHWAY c2.WP SIGNAL TRANSDUCTION THROUGH IL1R c2.WP SIGNAL TRANSDUCTION THROUGH IL1R c2.WP CANCER PATHWAYS c2.WP GLUTATHIONE METABOLISM c2.BANDRES RESPONSE TO CARMUSTIN MGMT 48HR UP c2.WP THYROID HORMONES PRODUCTION AND PERIPHERAL DOWNSTREAMS SIGNALING EFFECTS					
C2.KENNY CTNNB1 TARGETS UP C2.COULOUARN TEMPORAL TGFB1 SIGNATURE DN C2.ZHENG FOXP3 TARGETS IN T LYMPHOCYTE DN C2.IWANAGA CARCINOGENESIS BY KRAS PTEN DN C2.IWANAGA CARCINOGENESIS BY KRAS PTEN DN C2.YAO TEMPORAL RESPONSE TO PROGESTERONE CLUSTER 6 C2.MACAEVA PBMC RESPONSE TO IN C2.DOANE RESPONSE TO ANDROGEN UP C2.DOANE RESPONSE TO ANDROGEN UP C2.BIOCARTA PML PATHWAY C2.MULLIGHAN MLL SIGNATURE 1 DN C2.KYNG ENVIRONMENTAL STRESS RESPONSE C2.KEGG MEDICUS REFERENCE N GLYCAN PRECURSOR BIOSYNTHESIS GLC 6P TO MAN P DOL C2.KEGG MEDICUS REFERENCE N GLYCAN PRECURSOR BIOSYNTHESIS GLC 6P TO MAN P DOL C2.WP PROXIMAL TUBULE TRANSPORT					
c2.REACTOME G PROTEIN ACTIVATION c2.GARCIA TARGETS OF FLI1 AND DAX1 UP c2.WP BMP2WNT4FOXO1 PATHWAY IN PRIMARY ENDOMETRIAL STROMAL CELL DIFFERENTIATION c2.REACTOME INFLAMMASOMES c2.EIBIOCARTA EFP PATHWAY c2.KINSEY TARGETS OF EWSR1 FLII FUSION UP c2.HUANG DASATINIB RESISTANCE DN c2.STARK HYPPOCAMPUS 22Q11 DELETION DN c2.LEE TARGETS OF PTCH1 AND SUFU UP c2.WP RETINOBLASTOMA GENE IN CANCER c2.KEGG MEDICUS PATHOGEN HPV E6 TO NOTCH SIGNALING PATHWAY N00380 c2.GENTILE RESPONSE CLUSTER D3 c2.FARMER BREAST CANCER CLUSTER D3 c2.FEACTOME GAMMA CARBOXYLATION HYPUSINYLATION HYDROXYLATION AND ARYLSULFATASE ACTIVATION c2.BEGUM TARGETS OF PAX3 FOXO1 FUSION DN c2.MYLLYKANGAS AMPLIFICATION HOT SPOT 18					patho_cat_name Nerve sheath tumors Spindle and epithelioid tumors Gliomas
C2.BANDRES RESPONSE TO CARMUSTIN MGMT 48HR DN C2.WANG ADIPOGENIC GENES REPRESSED BY SIRT1 C2.REACTOME METABOLISM OF CARBOHYDRATES C2.STOSSI RESPONSE TO ESTRADIOL C2.LEE AGING NEOCORTEX DN C2.KEGG MEDICUS REFERENCE TNF P38 SIGNALING PATHWAY C2.WP TH17 CELL DIFFERENTIATION PATHWAY C2.ICHIBA GRAFT VERSUS HOST DISEASE D7 UP C2.LINDSTEDT DENDRITIC CELL MATURATION C C2.LI INDUCED T TO NATURAL KILLER DN C2.DARWICHE PAPILLOMA RISK LOW DN C2.DARWICHE PAPILLOMA RISK LOW DN C2.BEIER GIOMA STEM CELL DN C2.WP CHOLESTEROL BIOSYNTHESIS WITH SKELETAL DYSPLASIAS C2.REACTOME REMOVAL OF AMINOTERMINAL PROPEPTIDES FROM GAMMA CARBOXYLATED PROTEINS C2.REACTOME REMOVAL OF AMINOTERMINAL PROPEPTIDES FROM GAMMA CARBOXYLATED PROTEINS C2.REACTOME REGULATION OF BETA CELL DEVELOPMENT C2.NAKAMURA METASTASIS MODEL UP C2.REACTOME REGULATION OF BETA CELL DEVELOPMENT C2.NAKAMURA METASTASIS MODEL UP C2.HOFFMANN LARGE TO SMALL PRE BII LYMPHOCYTE UP					 Glioneuronal tumors
c2.CHARAFE BREAST CANCER LUMINAL VS BASAL UP c2.DAVICIONI RHABDOMYOSARCOMA PAX FOXOT FUSION C2.BIOCARTA FOSB PATHWAY c2.BIOCARTA FOSB PATHWAY c2.CASTELLANO NRAS TARGETS UP c2.DAVIES MULTIPLE MYELOMA VS MGUS UP c2.ROSS AML WITH CBFB MYH11 FUSION c2.ROSS AML WITH CBFB MYH11 FUSION c2.KAYO AGING MUSCLE UP c2.WP POLYCYSTIC KAYO AGING MUSCLE UP c2.WP POLYCYSTIC KAYO AGING MISO TARGETS UP c2.BIOCARTA CD40 PATHWAY c2.LEE BMP2 TARGETS UP c2.MARTORIATI MDM4 TARGETS NEUROEPITHELIUM DN c2.BIOCARTA CSK PATHWAY c2.REACTOME CREB3 FACTORS ACTIVATE GENES c2.SENESE HDAC1 AND CACC TARGETS UP c2.SUZUKI CTCFL TARGETS UP					
c2.NABA MATRISOME HIGHLY METASTATIC MELANOMA c2.WP LEUCINE ISOLEUCINE AND VALINE METABOLISM c2.WP BONE MORPHOGENIC PROTEIN SIGNALING AND REGULATION c2.CARRILLOREIXACH HEPATOBLASTOMA VS NORMAL UP c2.CREIGHTON ENDOCRINE THERAPY RESISTANCE 1 c2.FERRARI RESPONSE TO FENRETINIDE UP c2.REACTOME INTERLEUKIN 36 PATHWAY c2.ZHANG ANTIVIRAL RESPONSE TO RIBAVIRIN DN c2.ROYLANCE BREAST CANCER 16Q COPY NUMBER UP c2.WP MICROGLIA PATHOGEN PHAGOCYTOSIS PATHWAY c2.REACTOME SYNTHESIS OF UDP N ACETYL GLUCOSAMINE c2.WP WNT SIGNALING WP428 c2.ZHAN MULTIPLE MYELOMA CD1 VS CD2 DN c2.BIOCARTA ATM PATHWAY c2.GESERICK TERT TARGETS DN c2.KEGG VIRAL MYOCARDITIS c2.REACTOME N GLYCAN ANTENNAE ELONGATION IN THE MEDIAL TRANS GOLGI					
c2.MOREAUX B LYMPHOCYTE MATURATION BY TACI UP c2.REACTOME SIGNALING BY ACTIVIN c2.NIKOLSKY MUTATED AND AMPLIFIED IN BREAST CANCER c2.KEGG MEDICUS VARIANT MUTATION CAUSED ABERRANT ABETA TO CROSSTALK BETWEEN EXTRINSIC AND INTRINSIC APOPTOTIC PATHWAYS c2.KEGG MEDICUS REFERENCE STRAD STK11 TSC SIGNALING PATHWAY c2.SCHEIDEREIT IKK INTERACTING PROTEINS c2.WP NUCLEOTIDE EXCISION REPAIR IN XERODERMA PIGMENTOSUM c2.PID IL4 2PATHWAY c2.REACTOME INTERLEUKIN 4 AND INTERLEUKIN 13 SIGNALING c2.REACTOME ACTIVATION OF SMO c2.ZHAN MULTIPLE MYBLOMA MF DN c2.MALIK REPRESSED BY ESTROGEN c2.BOQUEST STEM CELL CULTURED VS FRESH UP c2.WP TP53 NETWORK c2.JOHANSSON GLIOMAGENESIS BY PDGFB DN c2.WP SYNTHESIS OF CERAMIDES AND 1DEOXYCERAMIDES c2.OZEN MIR125B1 TARGETS					
C2.REACTOME TRAF6 MEDIATED NF KB ACTIVATION C2.KEGG MEDICUS PATHOGEN HSV GD TO HVEM NFKB SIGNALING PATHWAY C2.BIOCARTA IL1R PATHWAY C2.AMIT EGF RESPONSE 120 MCF10A C2.VALK AML CLUSTERS C2.ELVIDGE HIF1A TARGETS DN C2.WP ZINC HOMEOSTASIS C2.ELVIDGE HIF1A TARGETS DN C2.WP GPR40 PATHWAY C2.BIOCARTA RB PATHWAY C2.BIOCARTA RB PATHWAY C2.ZHAN VARIABLE EARLY DIFFERENTIATION GENES UP C2.REACTOME NCAM'I INTERACTIONS C2.WANG RESPONSE TO BEXAROTENE DN C2.WIEMANN TELOMERE SHORTENING AND CHRONIC LIVER DAMAGE UP C2.FERREIRA EWINGS SARCOMA UNSTABLE VS STABLE DN C2.KILIGAN TARGETS OF EWS FL1F FUSION DN C2.CHIARETTI T ALL RELAPSE PROGNOSIS C2.REACTOME ACETYLCHOLINE NEUROTRANSMITTER RELEASE CYCLE C2.REACTOME ACETYLCHOLINE NEUROTRANSMITTER RELEASE CYCLE C2.REACTOME BURD TRANSMITTER RELEASE CYCLE C2.REACTOME SHC1 EVENTS IN ERBB2 SIGNALING					
c2.KUMAR AUTOPHAGY NETWORK c2.WP GPR143 IN MELANOCYTES AND RETINAL PIGMENT EPITHELIUM CELLS c2.WP MODULATORS OF TCR SIGNALING AND T CELL ACTIVATION c2.HEIDENBLAD AMPLICON 8Q24 UP c2.SHEDDEN LUNG CANCER GOOD SURVIVAL A5 c2.BLANCO MELO BRONCHIAL EPITHELIAL CELLS INFLUENZA A INFECTION c2.LIU PROSTATE CANCER UP c2.LIU PROSTATE CANCER UP c2.KEGG MEDICUS REFERENCE GLYCOSAMINOGLYCAN BIOSYNTHESIS LINKAGE TETRASACCHARIDE c2.MORI IMMATURE B LYMPHOCYTE c2.WP MAMMARY GLAND DEVELOPMENT EMBRYONIC DEVELOPMENT STAGE 1 OF 4 c2.GOLDRATH ANTIGEN RESPONSE c2.BIOCARTA GABA PATHWAY c2.REACTOME DISEASES OF CARBOHYDRATE METABOLISM c2.ENGELMANN CANCER PROGENITORS UP c2.REACTOME ATTACHMENT OF GPI ANCHOR TO UPAR c2.REACTOME ZINC EFFLUX AND COMPARTMENTALIZATION BY THE SLC30 FAMILY			7000		
c2.KEGG MEDICUS REFERENCE NODAL SIGNALING PATHWAY c2.FONTAINE THYROID TUMOR UNCERTAIN MALIGNANCY UP c2.BHAT ESR1 TARGETS VIA AKT1 DN c2.HUTTMANN B CLL POOR SURVIVAL DN c2.WINNEPENNINCKX MELANOMA METASTASIS UP c2.KAUFFMANN DNA REPLICATION GENES c2.SARTIPY BIUNTED BY INSULIN RESISTANCE UP c2.COLINA TARGETS OF 4EBP1 AND 4EBP2 c2.BRUINS UVC RESPONSE EARLY LATE c2.LEE LIVER CANCER CIPROFIBRATE UP c2.CHICAS RB1 TARGETS GROWING c2.WOTTON RUNX TARGETS UP c2.KEGG MEDICUS REFERENCE GPCR PI3K SIGNALING PATHWAY c2.KEGG TYPE II DIABETES MELLITUS c2.KIM PTEN TARGETS DN c2.KIM PTEN TARGETS DN c2.KARKS HDAC TARGETS DN c2.TAKEDA TARGETS OF NUP98 HOXA9 FUSION 16D DN					
C2.REACTOME MISCELLANEOUS TRANSPORT AND BINDING EVENTS C2.REACTOME PI 3K CASCADE FGFR1 C2.COATES MACROPHAGE M1 VS M2 DN C2.IWANAGA CARCINOGENESIS BY KRAS DN C2.IWANAGA CARCINOGENESIS BY KRAS DN C2.IWANOVA HEMATOPOIESIS INTERMEDIATE PROGENITIOR C2.AMBROSINI FLAVOPIRIDOL TREATMENT TP53 C2.KEGG MEDICUS REFERENCE DOUBLE STRAND BREAK SIGNALING C2.WANG LSD1 TARGETS DN C2.WP OSTEOBLAST SIGNALING C2.PANGAS TUMOR SUPPRESSION BY SMAD1 AND SMAD5 DN C2.YU MYC TARGETS UP C2.REACTOME HEPARAN SULFATE HEPARIN HS GAG METABOLISM C2.PURBEY TARGETS OF CTBP1 NOT SATB1 DN C2.REACTOME ACTIVATION OF CASPASES THROUGH APOPTOSOME MEDIATED CLEAVAGE C2.NUYTTEN NIPP1 TARGETS UP C2.MIYAGAWA TARGETS OF EWSR1 ETS FUSIONS DN C2.WU ALZHEIMER DISEASE UP					
C2.WP PATHOPHYSIOLOGICAL ROLES OF DUX4 IN FSHD1 C2.ACOSTA PROLIFERATION INDEPENDENT MYC TARGETS DN C2.VERHAAK AML WITH NPM1 MUTATED DN C2.GEISS RESPONSE TO DSRNA UP C2.GAUSSMANN MLL AF4 FUSION TARGETS F UP C2.BOYLAN MULTIPLE MYELOMA PCA3 DN C2.LIU TARGETS OF VMYB VS CMYB DN C2.LIU TARGETS OF VMYB VS CMYB DN C2.CALL EUKEMIC STEM CELL UP C2.KIM WT1 TARGETS 8HR DN C2.ELVIDGE HIF1A AND HIF2A TARGETS UP C2.SCHOEN FKB SIGNALING C2.MORI EMU MYC LYMPHOMA BY ONSET TIME UP C2.CONRAD STEM CELL C2.BROWNE HCMV INFECTION 18HR DN C2.REACTOME TRANSCRIPTION OF E2F TARGETS UNDER NEGATIVE CONTROL BY DREAM COMPLEX C2.CHAR EARLY DIFFERENTIATION GENES DN C2.DELACROIX RAR BOUND ES					
c2.JAATINEN HEMATOPOIETIC STEM CELL UP c2.NIKOLSKY OVERCONNECTED IN BREAST CANCER c2.ELLWOOD MYC TARGETS UP c2.FARMER BREAST CANCER CLUSTER 5 c2.HOFFMANN PRE BI TO LARGE PRE BII LYMPHOCYTE UP c2.KRASNOSELSKAI LIF3 TARGETS UP c2.VALK AML CLUSTER 3 c2.CLAUS PGR POSITIVE MENINGIOMA UP c2.REACTOME INTERFERON A LPHA BETTA SIGNALING c2.KEGG ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY c2.REACTOME ADHERENS JUNCTIONS INTERACTIONS c2.REACTOME ADHERENS JUNCTIONS INTERACTIONS c2.REACTOME ADHERENS JUNCTIONS INTERACTIONS c2.REACTOME ABHERENS JUNCTIONS IN					
C2.GENTILE UV RESPONSE CLUSTER D1 C2.TOTA TARGETS OF MIR34B AND MIR34C C2.WP SARSCOV2 B117 VARIANT ANTAGONISES INNATE IMMUNE ACTIVATION C2.WP STATIN INHIBITION OF CHOLESTEROL PRODUCTION C2.FEVR CTINNB1 TARGETS UP C2.OSADA ASCL1 TARGETS UP C2.OSADA ASCL1 TARGETS D1 C2.TERAMOTO OPN TARGETS CLUSTER 7 C2.BONCI TARGETS OF MIR15A AND MIR16 1 C2.MIKKELSEN DEDIFFERENTIATED STATE DN C2.KEGG APOPTOSIS C2.OISHI CHOLANGIOMA STEM CELL LIKE DN C2.GRAHAM CML QUIESCENT VS NORMAL QUIESCENT DN C2.ZHAN V1 LATE DIFFERENTIATION GENES DN C2.KEGG BASAL TRANSCRIPTION FACTORS C2.KEGG GLYCEROPHOSPHOLIPID METABOLISM C2.LUCAS HNF4A TARGETS UP C2.BERTUCCI INVASIVE CARCINOMA DUCTAL VS LOBULAR DN C2.NIKOLSKY BREAST CANCER 20012 Q13 AMPLICON C2.WP MEASLES VIRUS INFECTION					
c2.REACTOME NEGATIVE REGULATION OF TCF DEPENDENT SIGNALING BY DVL INTERACTING PROTEINS c2.WESTON VEGFA TARGETS 3HR c2.REACTOME NRAGE SIGNALS DEATH THROUGH JNK c2.REACTOME NRAGE SIGNALS DEATH THROUGH JNK c2.REACTOME NOTCH2 INTRACELLULAR DOMAIN REGULATES TRANSCRIPTION c2.MENSE HYPOXIA UP c2.LU TUMOR ENDOTHELIAL MARKERS UP c2.KRIGE AMINO ACID DEPRIVATION c2.BERTUCCI INVASIVE CARCINOMA DUCTAL VS LOBULAR UP c2.WP GLYCOSAMINOGLYCAN DEGRADATION c2.REACTOME METABOLISM OF LIPIDS c2.WP OLIGODENDROCYTE SPECIFICATION AND DIFFERENTIATION LEADING TO MYELIN COMPONENTS FOR CNS c2.CREIGHTON ENDOCRINE THERAPY RESISTANCE 4 c2.WP TRANSSULFURATION ONECARBON METABOLISM AND RELATED PATHWAYS c2.REACTOME RNA POLYMERASE I TRANSCRIPTION TERMINATION c2.WP BREAST CANCER PATHWAY c2.BROWNE HCMV INFECTION 14HR DN c2.WU HGF TARGETS INDUCED BY AKT1 6HR c2.WP NOVEL INTRACELLULAR COMPONENTS OF RIGILIKE RECEPTOR PATHWAY					
c2.WP ENDODERM DIFFERENTIATION c2.SHEDDEN LUNG CANCER POOR SURVIVAL A6 c2.QODNNELL METASTASIS DN c2.WP CLOCKCONTROLLED AUTOPHAGY IN BONE METABOLISM c2.WANG THOCH TARGETS DN c2.WANG THOCH TARGETS DN c2.WANG THOCH TARGETS DN c2.WANG THOCH TARGETS DN c2.WALK AML CLUSTER 6 c2.DACOSTA UV RESPONSE TO ANDROGEN UP c2.REACTOME SMAC XIAP REGULATED APOPTOTIC RESPONSE c2.SHEPARD CRASH AND BURN MUTANT UP c2.RAO BOUND BY SALL4 ISOFORM A c2.ZIRN TRETINOIN RESPONSE WT1 DN c2.CEBALLOS TARGETS OF TP53 AND MTY DN c2.ERANGAS AMPLIFICATION HOT SPOT 8 c2.BERNARD PPAPDC1B TARGETS DN c2.BERNARD PPAPDC1B TARGETS DN c2.GRAESSMANN APOPTOSIS BY DOXORUBICIN UP					
c2.WP G1 TO S CELL CYCLE CONTROL c2.YAMASHITA LIVER CANCER STEM CELL UP c2.REACTOME DISSOLUTION OF FIBRIN CLOT c2.KEGG TERPENOID BACKBONE BIOSYNTHESIS c2.KEGG MEDICUS VARIANT MUTATION INACTIVATED ATXN3 TO AUTOPHAGY VESICLE NUCLEATION c2.REACTOME PLATELET HOMEOSTASIS c2.MATZUK PREOVULATORY FOLLICLE c2.LICHIBA GRAFT VERSUS HOST DISEASE 35D UP c2.LIEN BREAST CARCINOMA METAPLASTIC VS DUCTAL UP c2.WIEDERSCHAIN TARGETS OF BMI1 AND PCGF2 c2.WP CHOLESTEROL METABOLISM c2.REACTOME GAP FILLING DNA REPAIR SYNTHESIS AND LIGATION IN GG NER c2.SANSOM WNT PATHWAY REQUIRE MYC c2.NEBEN AML WITH FLT3 OR NARS UP c2.REACTOME TELOMERE MAINTENANCE c2.HARRIS BRAIN CANCER PROGENITORS c2.KEGG MEDICUS REFERENCE HEPARAN SULFATE DEGRADATION c2.KEGG MEDICUS REFERENCE HEPARAN SULFATE DEGRADATION					
c2.OHASHI AURKA TARGETS c2.KEGG MEDICUS REFERENCE FLCN MTORC1 SIGNALING PATHWAY c2.BENPORATH PROLIFERATION c2.WANG METASTASIS OF BREAST CANCER ESR1 DN c2.WANG METASTASIS OF BREAST CANCER ESR1 DN c2.WH PEART DEVELOPMENT c2.HUANG GATA2 TARGETS DN c2.ZHENG GLIOBLASTOMA PLASTICITY UP c2.RIZ ERYTHROID DIFFERENTIATION 12HR c2.SPIELMAN LYMPHOBLAST EUROPEAN VS ASIAN 2FC DN c2.KONDO EZH2 TARGETS c2.BEROWNE HCMV INFECTION 6HR DN c2.KEGG TOLL LIKE RECEPTOR SIGNALING PATHWAY c2.PID INTEGRIN4 PATHWAY c2.PID INTEGRIN4 PATHWAY c2.REACTOME RHOBTBS ATPASE CYCLE c2.LUCAS HNF4A TARGETS DN c2.GEORGES TARGETS OF MIR192 AND MIR215 c2.TAKEDA TARGETS ON NUP98 HOXA9 FUSION 8D DN c2.BOCHKIS FOXA2 TARGETS					
c2.GRAESSMANN RESPONSE TO MC AND SERUM DEPRIVATION DN c2.KEGG ETHER LIPID METABOLISM c2.CONCANNON APOPTOSIS BY EPOXOMICIN DN c2.CHEOK RESPONSE TO MERCAPTOPURINE AND HD MTX UP c2.REACTOME PENTOSE PHOSPHATE PATHWAY c2.REACTOME PENTOSE PHOSPHATE PATHWAY c2.REACTOME REGULATION OF NPAS4 GENE TRANSCRIPTIVA c2.REACTOME REGULATION OF NPAS4 GENE TRANSCRIPTIVA c2.REACTOME REGULATION OF NPAS4 GENE TRANSCRIPTIVA c2.SCHAEFFER PROSTATE DEVELOPMENT 12HR UP c2.KEGG FRUCTOSE AND MANNOSE METABOLIST c2.VALK AML CLUSTER 10 c2.CADWELL ATG16L1 TARGETS DN c2.SMIRNOV CIRCULATING ENDOTHELIOCYTES IN CANCER DP c2.SCHUHMACHORYTES DN c2.SCHUHMACHORYTES DN c2.BILD HRAS ONCOGENIC SIGNATURE c2.WP MIRNA REGULATION OF P53 PATHWAY IN PROSTATE CANCER c2.GARGALOVIC RESPONSE TO OXIDIZED PHOSPHOLIPIDS SALMON UP c2.WAMMUNYOKOLI OVARIAN CANCER LMP UP					
C2.ZWANG CLASS 3 TRANSIENTLY INDUCED BY EGF C2.XVI RESPORTE TO TRETINOIN UP C2.NIKOLSKY BREAST CANCER 8Q12 Q22 AMPLICON C2.REACTOME BBSOME MEDIATED CARGO TARGETING TO CILIUM C2.GOUYER TUMOR INVASIVENESS C2.PETRETTO HEART MASS QTL CIS DN C2.URS ADIPOCYTE DIFFERENTIATION UP C2.KEGG MEDICUS REFERENCE TSH DUOX2 TG SIGNALING PATHON C2.WP NANOMATERIALINDUCED INFLAMMASOME ACTIVATION C2.WP NANOMATERIALINDUCED INFLAMMASOME ACTIVATION C2.REACTOME LONG TERM POTENTIATION C2.REACTOME ACTIVATION C2.REACTOME ACTIVATION C2.REACTOME ACTIVATION C3.REACTOME ACTIVATION C4.REACTOME ACTIVATION C5.REACTOME ACTIVATION C5.HOWLIN CITEDIT TARGETS UP C5.HOWLIN CITEDIT TARGETS UP C5.PUJANA BREAST CANCER WITH BRCA1 MUTATED UP C2.ROJIMA SFRP2 TARGETS UP C2.ROJIMA SFRP2 TARGETS UP					
C2.NOJIMA SFRP2 TARGETS UP C2.NAZAG TGFB1 SIGNALING DN C2.WP ATM SIGNALING IN DEVELOPMENT AND DISEASE C2.GARGALOVIC RESPONSE TO OXIDIZED PHOSPHOLIPIDS GREEN DN C2.REACTOME DISEASES OF HEMOSTASIS C2.MEBARKI HCC PROGENITOR WNT UP BLOCKED BY FZD8CRD C2.WP ENTEROCYTE CHOLESTERCL METABOLISM C2.RABARCZYK BCL.11B TARGETS DN C2.NAGASHIMA EGF SIGNALING UP C2.BANDRES RESPONSE TO CARMUSTIN WITHOUT MGMT 48HR UP C2.BANDRES RESPONSE TO CARMUSTIN WITHOUT MGMT 48HR UP C2.KEGG MEDICUS REFERENCE TRH TRHR PLCB PKC SIGNALING PATHWAY C2.TONKS TARGETS OF RUNX1 RUNX1T1 FUSION MONOCYTE DN C2.PID ARF6 PATHWAY C2.WP 2Q13 COPY NUMBER VARIATION SYNDROME C2.CKUMURA INFLAMMATORY RESPONSE LPS C2.GRAESSMANN APOPTOSIS BY SERUM DEPRIVATION UP C2.KERLEY RESPONSE TO CISPLATIN UP C2.KERLEY RESPONSE TO CISPLATIN UP C2.KERLEY RESPONSE TO CISPLATIN UP C2.TERAMOTO OPN TARGETS CLUSTER 3 C2.REACTOME RUNX2 REGULATES CHONDROCYTE MATURATION					
C2.REACTOME RUNX2 REGULATES CHONDROCYTE MATURATION C2.REACTOME SYNTHESIS OF PA C2.REACTOME SHC MEDIATED CASCADE FGFR1 C2.GRAESSMANN APOPTOSIS BY SERUM DEPRIVATION DN C2.PID RXR VDR PATHWAY C2.MCBRYAN PUBERTAL BREAST 4 5WK UP C2.SA REG CASCADE OF CYCLIN EXPR C2.FLECHNER BIOPSY KIDNEY TRANSPLANT REJECTED VS OK UP C2.KEGG MEDICUS REFERENCE FE TF TRANSPORT C2.WP APOE AND MIR146 IN INFLAMMATION AND ATHEROSCLEROSIS C2.WP APOE AND MIR146 IN INFLAMMATION AND ATHEROSCLEROSIS C2.WP DEVELOPMENT OF PULMONARY DENDRITIC CELLS AND MACROPHAGE SUBSETS C2.REACTOME INTERLEUKIN 20 FAMILY SIGNALING C2.KEGG AMINO SUGAR AND NUCLEOTIDE SUGAR METABOLISM C2.WP 1P36 COPY NUMBER VARIATION SYNDROME C2.TIAN THE SIGNALING NOT VIA NFKB C2.CHEN LIVER METABOLISM QTL. CIS C2.PID TCR PATHWAY C2.REACTOME TP53 REGULATES TRANSCRIPTION OF SEVERAL ADDITIONAL CELL DEATH GENES WHOSE SPECIFIC ROLES IN P53 DEPENDENT APOPTOSIS REMAIN UNCERTAIN C2.REACTOME BETA OXIDATION OF PRISTANOYL COA					
C2.REACTOME BETA OXIDATION OF PRISTANOYL COA C2.REACTOME IRF3 MEDIATED INDUCTION OF TYPE I IFN C2.KEGG MEDICUS REFERENCE IL6 FAMILY TO JAK STAT SIGNALING PATHWAY C2.REACTOME METHIONINE SALVAGE PATHWAY C2.YANG BREAST CANCER ESR1 UP C2.COWLING MYCN TARGETS C2.SHI SPARC TARGETS DN C2.BIOCARTA G2 PATHWAY C2.HERNANDEZ ABERRANT MITOSIS BY DOCETACEL 2NM DN C2.BIOCARTA G2 PATHWAY C3.MARIADASON RESPONSE TO BUTYRATE SULINDAC 4 C2.WP NUCLEAR RECEPTORS METAPATHWAY C2.WP NUCLEAR RECEPTORS METAPATHWAY C3.KIM MYCL1 AMPLIFICATION TARGETS UP C3.REACTOME SPHINGOLIPID METABOLISM C4.REACTOME SPHINGOLIPID METABOLISM C5.REACTOME RNA POLYMERASE III TRANSCRIPTION INITIATION FROM TYPE 3 PROMOTER C4.CECHEMNITZ RESPONSE TO PROSTAGLANDIN E2 UP C5.REACTOME ACTIVATION OF MATRIX METALLOPSILNASES C5.REACTOME ACTIVATION OF MATRIX METALLOPSILNASES C5.REACTOME INTERLEUKIN RECEPTOR SHC SIGNALING					
c2.REACTOME INTERLEUKIN RECEPTOR SHC SIGNALING c2.BHATI GZM ARREST BY ZMETHOXYDATIOL DN c2.KEGG MEDICUS VARIANT MLL ENL FUSION TO TRANSCRIPTIONAL ACTIVATION c2.KEGG MEDICUS VARIANT MLL ENL FUSION TO TRANSCRIPTIONAL ACTIVATION c2.KEGG PPAR SIGNALING PATHWAY c2.GOERING BLOOD HDL CHOLESTEROL QTL TRANS c2.NIKOLSKY BREAST CANCER 16Q24 AMPLICON c2.WANG IMMORTALIZED BY HOXA9 AND MEIS1 UP c2.TAKEDA TARGETS OF NUP98 HOXA9 FUSION 10D DN c2.ROZANOV MMP14 TARGETS DN c2.ROZANOV MMP14 TARGETS DN c2.BOYAULT LIVER CANCER UP c2.BOYAULT LIVER CANCER SIGNALING BY TYPE 1 INSULIN LIKE GROWTH FACTOR 1 RECEPTOR IGF1R c2.BUYTAMEA TARGETS OF CCND1 AND CDK4 UP c2.KEGG MEDICUS REFERENCE TAC3 TACR3 PLC PKC SIGNALING PATHWAY c2.BOYAUT TOMOR SUPPRESSION BY C0.13A1 UP					
c2.REACTOME PHENYLALANINE AND TYROSINE METABOLISM c2.NUNODA RESPONSE TO DASATINIB UP c2.MASSARWEH RESPONSE TO ESTRADIOL c2.LIAN NEUTROPHIL GRANULE CONSTITUENTS c2.WHITEHURST PACLITAXEL SENSITIVITY c2.KEGG MEDICUS REFERENCE TLA! 2 4 NFKB SIGNALING PATHWAY c2.MEDINA SMARCA4 TARGETS c2.REACTOME MATURATION OF PROTEIN 3A c2.REACTOME MATURATION OF PROTEIN 3A c2.REACTOME SIGNALING BY RETINOIC ACID c2.IBRAHIM NRF1 DOWN c2.REACTOME SYNTHESIS OF 12 EICOSATETRAENOIC ACID DERIVATIVES c2.REACTOME IRS MEDIATED SIGNALLING c2.SHIN B CELL LYMPHOMA CLUSTER 5 c2.SHO C3.SHIN CANCER SUBCLASS G3 DN c3.GAUSSMANN MLL AF4 FUSION TARGETS E DN c2.REACTOME TRANSPORT AND SYNTHESIS OF APS					
c2.REACTOME TRANSPORT AND SYNTHESIS OF PAPS c2.FARMER BREAST CANCER BASAL VS LULMINAL c2.WP MATRIX METALLOPROTEINASES c2.SCHAVOLT TARGETS OF TP53 AND TP63 c2.REACTOME KERATAN SULFATE DEGRADATION c2.KEGG MEDICUS VARIANT TMPRSS2 ERG FUSION TO TRANSCRIPTIONAL ACTIVATION c2.RORIE TARGETS OF EWSR1 FLI1 FUSION DN c2.SCHMIDT POR TARGETS IN LIMB BUD UP c2.BOYAULT LIVER CANCER SUBCLASS G6 DN c2.WP TOLLLIKE RECEPTOR SIGNALING c2.SMIRNOV RESPONSE TO IR 2HR UP c2.BOYLAN MULTIPLE MYELOMA D CLUSTER UP c2.ZEILSTRA CD44 TARGETS DN c2.WP MESODERMAL COMMITMENT PATHWAY c2.REACTOME GLYCOSAMINOGLYCAN METABOLISM c2.REACTOME GLYCOSAMINOGLYCAN TO SYNAPSES c2.VANTVEER BREAST CANCER BRCA1 UP c2.REACTOME PROTEIN INTERACTIONS AT SYNAPSES c2.VANTVEER BREAST CANCER BRCA1 UP c2.TEACTOME GLYCOSPHINGOLIPID CATABOLISM					
C2.REACTOME GLYCOSPHINGOLIPID CATABOLISM C2.HID BELTA NP63 PATHWAY C2.HEBERT MATRISOME TNBC BONE METASTASIS TUMOR CELL DERIVED C2.GARGALOVIC RESPONSE TO OXIDIZED PHOSPHOLIPIDS YELLOW DN C2.HOLLERN MICROACINAR BREAST TUMOR DN C2.MASSARWEH TAMOXIFEN RESISTANCE DN C2.MASSARWEH TAMOXIFEN RESISTANCE DN C2.REACTOME CASPASE ACTIVATION VIA DEPENDENCE RECEPTORS IN THE ABSENCE OF LIGAND C2.REACTOME TRNA PROCESSING IN THE NUCLEUS C2.ZHAN MULTIPLE MYELOMA PR DN C2.FIGUEROA AML METHYLATION CLUSTER 6 UP C2.ALCALAY AML BY NPM1 LOCALIZATION UP C2.SSALVA MIL12 TARGETS C2.SHEDDEN LUNG CANCER GOOD SURVIVAL A4 C2.SEGG MEDICUS REFERENCE DNA REPLICATION TERMINATION C2.WP COVID19 STRUCTURAL COVERAGE MAP C2.FIGUEROA MATURATION PACER RUBCN PIXKC3 C2 C2.PID HNF3B PATHWAY					
C2.PID HNF3B PATHWAY C2.ROESSLER LIVER CANCER METASTASIS UP C2.HOSHIDA LIVER CANCER SUBCLASS S3 C2.WP ACQUIRED PARTIAL LIPODYSTROPHY BARRAQUERSIMONS SYNDROME C2.IVANOVA HEMATOPOIESIS STEM CELL LONG TERM C2.REACTOME CANNITION OF RITK OF RITK RAS ERK SIGNALING UBIQUITINATION OF RITK BY CBL C2.REACTOME METOSOLS C2.REACTOME MEIOSIS C2.VANTVEER BREAST CANCER POOR PROGNOSIS C2.WP ACQUIRED PARTIAL LIPODYSTROPHY BARRAQUERSIMONS SYNDROME C2.REACTOME METOSIS C2.KEGG MEDICUS REFERENCE REGULATION OF GF RITK RAS ERK SIGNALING UBIQUITINATION OF RITK BY CBL C2.REACTOME MEIOSIS C2.KEGG MEDICUS ENV FACTOR NNK NNN TO CHRNAT E2F SIGNALING PATHWAY C2.WP PTF1A RELATED REGULATORY PATHWAY C2.WP PTF1A RELATED REGULATORY PATHWAY C2.DUTERTRE ESTRADIOL RESPONSE 6HR DN C2.DUTERTRE ESTRADIOL RESPONSE 6HR DN C2.REACTOME METAL ION SLC TRANSPORTERS C2.REACTOME G2 M DNA DAMAGE CHECKPOINT C2.PLASARI TGFB1 TARGETS 10HR DN C2.TURASHVILI BREAST NORMAL DUCTAL VS LOBULAR UP C2.TURASHVILI BREAST NORMAL DUCTAL VS LOBULAR UP					
C2.TURASHVILI BREAST NORMAL DUCTAL VS LOBULAR UP C2.BROWNE HCMV INFECTION 2HR DN C2.KEGG MEDICUS REFERENCE NUCLEAR INITIATED ESTROGEN SIGNALING PATHWAY C2.TERAO AOX4 TARGETS SKIN DN C2.REACTOME GLYCEROPHOSPHOLIPID BIOSYNTHESIS C2.KYNG DNA DAMAGE BY UV C2.MIKKELSEN NPC LCP WITH H3K4ME3 C2.CUI TCF21 TARGETS 2 UP C2.LE AGING CEREBELLUM DN C2.LEE AGING CEREBELLUM DN C2.LEE AGING CEREBELLUM DN C2.REACTOME METABOLISM OF FAT SOLUBLE YITAMINS C2.KEGG MEDICUS REFERENCE CA2 ENTRY STORE OPERATED CA2 CHANNEL C2.REACTOME MECP2 REGULATES TRANSCRIPTION FACTORS C2.MAHAJAN RESPONSE TO LILA UP C2.REACTOME INTERLEUKIN 21 SIGNALING C2.HESS TARGETS OF HOXA9 AND MEIS1 DN C2.HESS TARGETS OF HOXA9 AND MEIS1 DN C2.HERNANDEZ ABERRANT MITOSIS BY DOCETACEL 4NM UP					
c2.HERNANDEZ ABERRANT MITOSIS BY DOCETACEL 4NM UP c2.BOYAULT LIVER CANCER SUBICLASS G6 UP c2.SWEET KRAS TARGETS DN c2.MEBARKI HCC PROGENITOR UP c2.LANDIS ERBB2 BREAST PRENEOPLASTIC UP c2.LANDIS ERBB2 BREAST PRENEOPLASTIC UP c2.KANNAN TP53 TARGETS DN c2.WHITFIELD CELL CYCLE G2 c2.WHITFIELD CELL CYCLE G2 c2.WANG CISPLATIN RESPONSE AND XPC UP c2.HALMOS CEBPA TARGETS DN c2.TURASHVILI BREAST CARCINOMA DUCTAL VS LOBULAR DN c2.FIGUEROA AML METHYLATION CLUSTER 1 DN c2.BROWNE HCMV INFECTION 4HR DN c2.BROWNE HCMV INFECTION 4HR UP c2.ZHAN MULTIPLE MYELOMA MF UP c2.KEGG ARGININE AND PROLINE METABOLISM c2.BROWNE HCMV INFECTION 4HR UP c2.CENENT ESR1 TARGETS NOT VIA AKT1 DN c2.BROWNE HCMV INFECTION 4 TO THE MYELOMA MF UP					
c2.BHAT ESR1 TARGETS NOT VIA AKT1 DN c2.KEGG CELL ADHESION MOLECULES CAND c2.BIOCARTA MELANOCYTE PATHWAY c2.BIOCARTA MELANOCYTE PATHWAY c2.GRAHAM CML DIVIDING VS NORMAL QUIESCENT DN c2.KEGG MEDICUS PATHOGEN HTLV 1 TAX TO NFY MEDIATED TRANSCRIPTION c2.REACTOME N TO NFY MEDIATED TRANSCRIPTION c2.REACTOME N TO NATURAL KILLER UP c2.HOFFMANN SMALL PRE BII TO IMMATURE B LYMPHOCYTE UP c2.KEGG ALANINE ASPARTATE AND GLUTAMATE METABOLISM c2.REACTOME PEROXISOMAL PROTEIN IMPORT c2.XU HGF TARGETS INDUCED BY AKT1 48H R DN c2.ZHAN MULTIPLE MYELOMA CD2 DN c2.SIMBULAN UV RESPONSE NORMAL UP c2.GRAHAM NORMAL QUIESCENT VS NORMAL DIVIDING UP c2.REACTOME ZBP1 DAI MEDIATED INDUCTION OF TYPE I IFNS				-0.2 0.0 0.2	
c2.REACTOME ZBP1 DAI MEDIATED INDUCTION OF TYPE I IFNS	•	2 0.0 0.2 z_s		-0.2 0.0 0.2	